Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2090655> ?p ?o }
Showing triples 1 to 60 of
60
with 100 triples per page.
- Q2090655 subject Q18706655.
- Q2090655 subject Q22570441.
- Q2090655 subject Q5856563.
- Q2090655 subject Q6973246.
- Q2090655 subject Q7204516.
- Q2090655 subject Q7469560.
- Q2090655 subject Q8297705.
- Q2090655 subject Q8744384.
- Q2090655 subject Q8965786.
- Q2090655 abstract "Fabomotizole (INN) (brand name Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety.Experiments of mice have shown antimutagenic and antiteratogenic properties.Fabomotizole has found little clinical use outside Russia and has not been evaluated by the FDA.".
- Q2090655 atcPrefix "N05".
- Q2090655 atcSuffix "BX04".
- Q2090655 bioavailability "43.64".
- Q2090655 casNumber "173352-39-1".
- Q2090655 fdaUniiCode "HDO6HX6NZU".
- Q2090655 iupacName "5-Ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole".
- Q2090655 pubchem "9862937".
- Q2090655 thumbnail Fabomotizole.svg?width=300.
- Q2090655 wikiPageWikiLink Q1225289.
- Q2090655 wikiPageWikiLink Q12831520.
- Q2090655 wikiPageWikiLink Q1330121.
- Q2090655 wikiPageWikiLink Q14863330.
- Q2090655 wikiPageWikiLink Q14873931.
- Q2090655 wikiPageWikiLink Q18029573.
- Q2090655 wikiPageWikiLink Q18356742.
- Q2090655 wikiPageWikiLink Q18706655.
- Q2090655 wikiPageWikiLink Q1981368.
- Q2090655 wikiPageWikiLink Q22570441.
- Q2090655 wikiPageWikiLink Q3271540.
- Q2090655 wikiPageWikiLink Q419559.
- Q2090655 wikiPageWikiLink Q4286560.
- Q2090655 wikiPageWikiLink Q5810370.
- Q2090655 wikiPageWikiLink Q5856563.
- Q2090655 wikiPageWikiLink Q62903.
- Q2090655 wikiPageWikiLink Q6811649.
- Q2090655 wikiPageWikiLink Q6973246.
- Q2090655 wikiPageWikiLink Q7204516.
- Q2090655 wikiPageWikiLink Q7469560.
- Q2090655 wikiPageWikiLink Q7512419.
- Q2090655 wikiPageWikiLink Q824258.
- Q2090655 wikiPageWikiLink Q8297705.
- Q2090655 wikiPageWikiLink Q8386.
- Q2090655 wikiPageWikiLink Q847705.
- Q2090655 wikiPageWikiLink Q8744384.
- Q2090655 wikiPageWikiLink Q8965786.
- Q2090655 atcPrefix "N05".
- Q2090655 atcSuffix "BX04".
- Q2090655 bioavailability "43.64".
- Q2090655 casNumber "173352".
- Q2090655 iupacName "5".
- Q2090655 pubchem "9862937".
- Q2090655 unii "HDO6HX6NZU".
- Q2090655 type ChemicalSubstance.
- Q2090655 type Drug.
- Q2090655 type ChemicalObject.
- Q2090655 type Thing.
- Q2090655 type Q8386.
- Q2090655 comment "Fabomotizole (INN) (brand name Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms.".
- Q2090655 label "Fabomotizole".
- Q2090655 depiction Fabomotizole.svg.